Literature DB >> 25714795

β-Amyloid and α-synuclein cooperate to block SNARE-dependent vesicle fusion.

Bong-Kyu Choi1, Jae-Yeol Kim, Moon-Yong Cha, Inhee Mook-Jung, Yeon-Kyun Shin, Nam Ki Lee.   

Abstract

Alzheimer's disease (AD) and Parkinson's disease (PD) are caused by β-amyloid (Aβ) and α-synuclein (αS), respectively. Ample evidence suggests that these two pathogenic proteins are closely linked and have a synergistic effect on eliciting neurodegenerative disorders. However, the pathophysiological consequences of Aβ and αS coexistence are still elusive. Here, we show that large-sized αS oligomers, which are normally difficult to form, are readily generated by Aβ42-seeding and that these oligomers efficiently hamper neuronal SNARE-mediated vesicle fusion. The direct binding of the Aβ-seeded αS oligomers to the N-terminal domain of synaptobrevin-2, a vesicular SNARE protein, is responsible for the inhibition of fusion. In contrast, large-sized Aβ42 oligomers (or aggregates) or the products of αS incubated without Aβ42 have no effect on vesicle fusion. These results are confirmed by examining PC12 cell exocytosis. Our results suggest that Aβ and αS cooperate to escalate the production of toxic oligomers, whose main toxicity is the inhibition of vesicle fusion and consequently prompts synaptic dysfunction.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25714795      PMCID: PMC4414064          DOI: 10.1021/acs.biochem.5b00087

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  58 in total

1.  Cross-seeding effects of amyloid β-protein and α-synuclein.

Authors:  Kenjiro Ono; Ryoichi Takahashi; Tokuhei Ikeda; Masahito Yamada
Journal:  J Neurochem       Date:  2012-07-23       Impact factor: 5.372

Review 2.  SNAREs--engines for membrane fusion.

Authors:  Reinhard Jahn; Richard H Scheller
Journal:  Nat Rev Mol Cell Biol       Date:  2006-08-16       Impact factor: 94.444

Review 3.  Amyloid oligomers: formation and toxicity of Abeta oligomers.

Authors:  Masafumi Sakono; Tamotsu Zako
Journal:  FEBS J       Date:  2010-02-09       Impact factor: 5.542

4.  Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.

Authors:  K A Conway; J C Rochet; R M Bieganski; P T Lansbury
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

5.  α-Synuclein can inhibit SNARE-mediated vesicle fusion through direct interactions with lipid bilayers.

Authors:  David C DeWitt; Elizabeth Rhoades
Journal:  Biochemistry       Date:  2013-03-27       Impact factor: 3.162

6.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.

Authors:  E Hirsch; A M Graybiel; Y A Agid
Journal:  Nature       Date:  1988-07-28       Impact factor: 49.962

7.  Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease.

Authors:  G M Halliday; D A McRitchie; H Cartwright; R Pamphlett; M A Hely; J G Morris
Journal:  J Clin Neurosci       Date:  1996-01       Impact factor: 1.961

8.  Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro.

Authors:  Jacqueline Burré; Manu Sharma; Theodoros Tsetsenis; Vladimir Buchman; Mark R Etherton; Thomas C Südhof
Journal:  Science       Date:  2010-08-26       Impact factor: 47.728

9.  Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease.

Authors:  Pravat K Mandal; Jay W Pettegrew; Eliezer Masliah; Ronald L Hamilton; Ratna Mandal
Journal:  Neurochem Res       Date:  2006-09-01       Impact factor: 4.414

Review 10.  Examining the mechanisms that link β-amyloid and α-synuclein pathologies.

Authors:  Samuel E Marsh; Mathew Blurton-Jones
Journal:  Alzheimers Res Ther       Date:  2012-04-30       Impact factor: 6.982

View more
  9 in total

1.  Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model.

Authors:  Brian Spencer; Paula A Desplats; Cassia R Overk; Elvira Valera-Martin; Robert A Rissman; Chengbiao Wu; Michael Mante; Anthony Adame; Jazmin Florio; Edward Rockenstein; Eliezer Masliah
Journal:  J Neurosci       Date:  2016-07-27       Impact factor: 6.167

2.  Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson's patient brain-derived α-synuclein.

Authors:  Colleen S Limegrover; Raymond Yurko; Nicholas J Izzo; Kelsie M LaBarbera; Courtney Rehak; Gary Look; Gilbert Rishton; Hank Safferstein; Susan M Catalano
Journal:  J Neurosci Res       Date:  2021-01-22       Impact factor: 4.164

3.  Impaired synaptic function is linked to cognition in Parkinson's disease.

Authors:  Per Selnes; Ane Løvli Stav; Krisztina K Johansen; Atle Bjørnerud; Christopher Coello; Eirik Auning; Lisa Kalheim; Ina Selseth Almdahl; Erik Hessen; Henrik Zetterberg; Kaj Blennow; Dag Aarsland; Tormod Fladby
Journal:  Ann Clin Transl Neurol       Date:  2017-08-31       Impact factor: 4.511

Review 4.  Looking at the recent advances in understanding α-synuclein and its aggregation through the proteoform prism.

Authors:  Vladimir N Uversky
Journal:  F1000Res       Date:  2017-04-20

5.  Neurodegenerative Disease Related Proteins Have Negative Effects on SNARE-Mediated Membrane Fusion in Pathological Confirmation.

Authors:  Chen Hou; Yongyao Wang; Jiankang Liu; Changhe Wang; Jiangang Long
Journal:  Front Mol Neurosci       Date:  2017-03-21       Impact factor: 5.639

6.  Amyloid-Beta Induced Changes in Vesicular Transport of BDNF in Hippocampal Neurons.

Authors:  Bianca Seifert; Robert Eckenstaler; Raik Rönicke; Julia Leschik; Beat Lutz; Klaus Reymann; Volkmar Lessmann; Tanja Brigadski
Journal:  Neural Plast       Date:  2016-01-10       Impact factor: 3.599

Review 7.  Alpha-synuclein Toxicity in the Early Secretory Pathway: How It Drives Neurodegeneration in Parkinsons Disease.

Authors:  Ting Wang; Jesse C Hay
Journal:  Front Neurosci       Date:  2015-11-12       Impact factor: 4.677

Review 8.  Mitochondrial dysfunction in Parkinson's disease.

Authors:  Qingsong Hu; Guanghui Wang
Journal:  Transl Neurodegener       Date:  2016-07-22       Impact factor: 8.014

Review 9.  Immunotherapies for Aging-Related Neurodegenerative Diseases-Emerging Perspectives and New Targets.

Authors:  Somin Kwon; Michiyo Iba; Changyoun Kim; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.